Articles tagged with Checkpoint Pathways
Researchers at UZH have identified a new function of checkpoint inhibitors in promoting tissue healing, which could help treat fibrosis and chronic wounds. The study found that TIGIT upregulates a growth factor critical for repairing tissue after viral infections.
Researchers have developed a TIM-3 decoy that improves the effectiveness of CAR-T cell therapy in treating B-cell Acute Lymphoblastic Leukemia. The decoy blocks the interaction between the tumor and immune cells, allowing CAR-T cells to persist and attack cancer cells more effectively.
Researchers at Rice University have discovered a promising new immunological pathway to treat stubborn bone tumors in breast cancer patients. The glyco-immune checkpoint axis, involving protein Siglec-15, plays a crucial role in hiding bone tumors from the immune system.
Patients with advanced kidney cancer who receive second-line treatment with a combination of atezolizumab and cabozantinib do not experience improved progression-free survival or overall survival compared to those treated with cabozantinib alone. The study also finds higher toxicity levels in patients receiving the combination therapy.
Researchers discovered that 15-deoxy-prostamide-J2 induces ER stress-mediated apoptosis selectively in tumor cells, reducing melanoma growth. The molecule activates PERK, IP3R, and the mitochondrial permeability transition pore, leading to cell death.
Researchers found that ruxolitinib, a clinically approved drug, suppresses ICB-resistant melanomas by reprogramming TILs and relying on host TNF signaling. This discovery offers a potential target for bypassing therapeutic resistance in advanced melanoma patients.
Researchers at Cedars-Sinai Cancer have identified a novel immune checkpoint pathway that could lead to better understanding and treatment of hepatocellular carcinoma. The study suggests that blocking this pathway, combined with immunotherapy, may provide a new therapeutic strategy for liver cancer.
Researchers have shed light on how immune checkpoint protein LAG3 modulates T cell activity, providing crucial information for the development of new LAG3-blocking therapies. The study found that LAG3 suppresses T cell activation by disrupting coreceptor-Lck association, even in the absence of MHC Class II molecules.
MUSC Hollings Cancer Center researchers discovered a novel mechanism showing how a certain gene mutation can allow tumors to evade detection by the immune system in colorectal cancer patients. The study found that APC mutations lead to increased levels of PD-L1, which allows tumors to evade T-cell function and increase immunosuppression.
Researchers developed a novel probe to study how a 'matchmaker' molecule generates a 'wait' signal at kinetochores, ensuring accurate chromosome inheritance. This discovery provides insight into how accuracy of chromosome inheritance can be lowered in diseases like cancer.
Researchers have identified a minimal DNA structure that activates the ATR-mediated DNA damage checkpoint in a cell-free system. This discovery enables precise control and quantitative probing of checkpoint signaling responses.
A study by Tufts University researcher Catherine Freudenreich reveals that cells with certain DNA mutations may activate a surveillance system to repair damaged DNA, leading to cell death. The findings could lead to advances in treating diseases such as Huntington's disease and muscular dystrophy.